Danish microbiome research company Clinical Microbiomics has received a €10 million investment from ‘Health for Life Capital II’, managed by Seventure Partners.
Microbiome venture capitalists Seventure Partners have backed growth companies in the microbiome field with funding through ‘Health for Life I’ and ‘Health for Life II’ since 2013.
Microbiome science is considered to be the next frontier in addressing urgent health challenges. Organisations worldwide are exploring the potential for microbiome science to help people live better lives; from novel nutritional products and next-generation probiotics to new ways to diagnose, treat and prevent disease. However, the complexity of microbiome science remains a challenge in bringing new solutions to market.
Founded in 2015, Clinical Microbiomics is supporting the pharmaceutical industry in Phase III clinical trials through its GCP-compliant microbiome research services. The company hosts 30k+ samples linking 3M+ bacterial strains to clinical phenotypes in its data-warehouse.
Isabelle de Cremoux, CEO and Managing Partner at Seventure Partners, commented: “Incredible progress has been made in understanding the link between the microbiota and our health in the past years, but there is still much more to be accomplished.
“Our investment will enable Clinical Microbiomics to invest even further to lead the way with innovative concepts and services at pharma standards for this field, and we believe their work will play a critical role in unleashing the potential of microbiome science.”
The funds raised will be invested to advance Clinical Microbiomics’ microbiome profiling and systems biology platform, and to expand the service offering within multi-omics data integration, as well as to build further presence in key markets starting with the US.
Anders Grøn, CEO at Clinical Microbiomics, added: “Our vision is a world where people are healthier because we understand how to improve our inner ecology – the microbiome. We challenge the idea that the complexity of the microbiome prevents us from exploring its potential to tackle the most pressing health questions of our time.”
